Clinical Efficacy of Olaparib in IDH1/IDH2- Mutant Mesenchymal Sarcomas.

Joseph Paul Eder Deborah B DoroshowKhanh T DoVicki L KeedyJeffrey S Sklar Peter M GlazerRanjit BindraGeoffrey I Shapiro

Published in: JCO precision oncology (2022)

These results indicate preliminary activity of PARP inhibition in patients with IDH1/2-mutant chondrosarcoma and pulmonary epithelioid hemangioendothelioma. Further studies of PARP inhibitors alone and in combination in this patient population are warranted.

Keyphrases

wild type
low grade
dna damage
dna repair
high grade
pulmonary hypertension
stem cells
bone marrow
case report
case control
oxidative stress